DE60324416D1 - Verwendung von edg rezeptor bindenden wirkstoffen für die krebstherapie - Google Patents

Verwendung von edg rezeptor bindenden wirkstoffen für die krebstherapie

Info

Publication number
DE60324416D1
DE60324416D1 DE60324416T DE60324416T DE60324416D1 DE 60324416 D1 DE60324416 D1 DE 60324416D1 DE 60324416 T DE60324416 T DE 60324416T DE 60324416 T DE60324416 T DE 60324416T DE 60324416 D1 DE60324416 D1 DE 60324416D1
Authority
DE
Germany
Prior art keywords
receptor binding
binding agents
cancer therapy
edg receptor
sphingosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60324416T
Other languages
German (de)
English (en)
Inventor
Thomas Baumruker
Volker Brinkmann
Montagne Kenneth Richard La
Peter T Lassota
Diana Mechtcheriakova
Jeanette Marjorie Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0211261A external-priority patent/GB0211261D0/en
Priority claimed from GB0217150A external-priority patent/GB0217150D0/en
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of DE60324416D1 publication Critical patent/DE60324416D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60324416T 2002-05-16 2003-05-15 Verwendung von edg rezeptor bindenden wirkstoffen für die krebstherapie Expired - Lifetime DE60324416D1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0211261A GB0211261D0 (en) 2002-05-16 2002-05-16 Organic compounds
US39041102P 2002-06-20 2002-06-20
GB0217150A GB0217150D0 (en) 2002-07-24 2002-07-24 Organic compounds
US44973903P 2003-02-24 2003-02-24
PCT/EP2003/005125 WO2003097028A1 (en) 2002-05-16 2003-05-15 Use of edg receptor binding agents in cancer

Publications (1)

Publication Number Publication Date
DE60324416D1 true DE60324416D1 (de) 2008-12-11

Family

ID=29554311

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60324416T Expired - Lifetime DE60324416D1 (de) 2002-05-16 2003-05-15 Verwendung von edg rezeptor bindenden wirkstoffen für die krebstherapie

Country Status (22)

Country Link
US (2) US20090209495A1 (enExample)
EP (3) EP1505959B1 (enExample)
JP (3) JP5227492B2 (enExample)
KR (1) KR20120125398A (enExample)
CN (1) CN1652757B (enExample)
AT (1) ATE412408T1 (enExample)
AU (1) AU2003240655B2 (enExample)
BR (1) BR0311173A (enExample)
CA (1) CA2483594C (enExample)
CY (1) CY1108719T1 (enExample)
DE (1) DE60324416D1 (enExample)
DK (1) DK1505959T3 (enExample)
ES (1) ES2316758T3 (enExample)
IL (3) IL164838A (enExample)
MX (1) MXPA04011384A (enExample)
NO (2) NO334074B1 (enExample)
NZ (2) NZ560662A (enExample)
PL (1) PL372103A1 (enExample)
PT (1) PT1505959E (enExample)
SI (1) SI1505959T1 (enExample)
WO (1) WO2003097028A1 (enExample)
ZA (1) ZA200408575B (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20010688A1 (it) 2001-11-21 2003-05-21 Univ Roma Composti immunoregolatori.
DE60328161D1 (de) 2002-01-11 2009-08-13 Daiichi Sankyo Co Ltd Aminoalkoholderivat oder phosphonsäurederivat und diese enthaltende medizinische zusammensetzung
GB2405642B (en) * 2002-06-07 2007-03-28 Es Cell Int Pte Ltd Methods of regulating differentiation in stem cells
WO2004074297A1 (ja) * 2003-02-18 2004-09-02 Kyorin Pharmaceutical Co., Ltd. アミノホスホン酸誘導体とその付加塩及びs1p受容体調節剤
GB0500020D0 (en) * 2005-01-04 2005-02-09 Novartis Ag Organic compounds
CN1921847B (zh) 2004-02-24 2010-06-16 三共株式会社 氨基醇化合物
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
JP4993407B2 (ja) * 2004-08-04 2012-08-08 大正製薬株式会社 トリアゾール誘導体
BRPI0514316A (pt) 2004-08-13 2008-06-10 Praecis Pharm Inc métodos e composições para modulação de atividade de receptor de esfingosina-1-fosfato (s1p)
ES2410866T3 (es) * 2004-10-28 2013-07-03 Lpath, Inc. Composiciones y procedimientos para el tratamiento y prevención de enfermedades hiperproliferativas
GB0513431D0 (en) 2005-06-30 2005-08-10 Kherion Technology Ltd Prophylactic compositions and uses
GT200600350A (es) * 2005-08-09 2007-03-28 Formulaciones líquidas
EP1988083B1 (en) 2006-02-03 2014-04-02 Taisho Pharmaceutical Co., Ltd. Triazole derivative
RU2395499C2 (ru) 2006-02-06 2010-07-27 Тайсо Фармасьютикал Ко., Лтд. Ингибитор связывания сфингозин-1-фосфата
AU2007234380A1 (en) * 2006-04-06 2007-10-11 Novartis Ag Combination of organic compounds
US7862812B2 (en) 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
EP1923058A1 (en) * 2006-09-26 2008-05-21 Novartis AG Coated pharmaceutical composition comprising an S1P agonist or modulator
US8444970B2 (en) * 2006-10-27 2013-05-21 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions
SI2177512T1 (sl) 2007-08-01 2012-06-29 Taisho Pharmaceutical Co Ltd Inhibitor vezave S1P1
EP2177521A1 (en) 2008-10-14 2010-04-21 Almirall, S.A. New 2-Amidothiadiazole Derivatives
CN102209705A (zh) * 2008-11-11 2011-10-05 诺瓦提斯公司 芬戈莫德盐酸盐的结晶形式
PE20120012A1 (es) * 2008-11-11 2012-02-02 Novartis Ag Sales de fingolimod
BRPI0923213A2 (pt) 2008-12-22 2016-01-26 Novaris Ag regime de dosagem de um agonista do receptor para s1p.
SI3409274T1 (sl) 2008-12-22 2020-03-31 Novartis Ag Režim odmerjanja za S1P receptor agonist
EP2202232A1 (en) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
EP2210890A1 (en) 2009-01-19 2010-07-28 Almirall, S.A. Oxadiazole derivatives as S1P1 receptor agonists
KR20120032538A (ko) * 2009-07-24 2012-04-05 라티오팜 게엠베하 핀골리모드 염의 제조 방법
EP2305660A1 (en) 2009-09-25 2011-04-06 Almirall, S.A. New thiadiazole derivatives
AU2010101513B4 (en) 2009-09-29 2016-05-05 Novartis Ag Dosage regimen of an S1P receptor modulator
EP2343287A1 (en) 2009-12-10 2011-07-13 Almirall, S.A. New 2-aminothiadiazole derivatives
EP2366702A1 (en) 2010-03-18 2011-09-21 Almirall, S.A. New oxadiazole derivatives
EP2390252A1 (en) 2010-05-19 2011-11-30 Almirall, S.A. New pyrazole derivatives
WO2012071524A1 (en) 2010-11-24 2012-05-31 Ratiopharm Gmbh Arylsulfonate salts of fingolimod and processes for preparation thereof
FR2968556B1 (fr) 2010-12-13 2013-12-27 Centre Nat Rech Scient Inhibiteurs des infections a vih et leurs utilisations
UA114283C2 (uk) 2011-01-07 2017-05-25 Новартіс Аг Композиції імуносупресантів
CN106278999B (zh) 2011-02-07 2019-10-25 比奥根Ma公司 S1p调节剂
WO2013057212A1 (en) 2011-10-21 2013-04-25 Novartis Ag Dosage regimen for an s1p receptor modulator or agonist
JP6033791B2 (ja) * 2011-12-23 2016-11-30 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 新規ｓ１ｐ受容体調整薬
US10273234B2 (en) 2012-08-06 2019-04-30 Biogen Ma Inc. Compounds that are S1P modulating agents and/or ATX modulating agents
US9499485B2 (en) 2012-08-06 2016-11-22 Biogen Ma Inc. Compounds that are S1P modulating agents and/or ATX modulating agents
EP2922821B1 (en) 2012-11-20 2019-07-31 Biogen MA Inc. S1p and/or atx modulating agents
WO2014081752A1 (en) 2012-11-20 2014-05-30 Biogen Idec Ma Inc. S1p and/or atx modulating agents
AU2014212465B2 (en) 2013-01-29 2018-07-12 Biogen Ma Inc. S1P modulating agents
TW201446768A (zh) 2013-03-15 2014-12-16 Biogen Idec Inc S1p及/或atx調節劑
CN103417970A (zh) * 2013-08-15 2013-12-04 泰山医学院 雌激素上调内皮系统保护分子鞘氨醇1-磷酸的应用
WO2016135644A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
EP3443986A1 (en) 2017-08-17 2019-02-20 AC BioScience Enhancement of chemotherapy efficiency by sphingosine-1-phosphate

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36730A0 (en) * 1970-05-28 1971-06-23 Chemagro Corp Phosphonamidothioates,their preparation and their use as herbicides and/or plant growth regulators
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
LU88769I2 (fr) 1982-07-23 1996-11-05 Zeneca Ltd Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R))
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
GB8517360D0 (en) 1985-07-09 1985-08-14 Erba Farmitalia Substituted androsta-1,4-diene-3,17-diones
IL86632A0 (en) 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
TW225528B (enExample) 1992-04-03 1994-06-21 Ciba Geigy Ag
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
EP0627406B1 (en) * 1992-10-21 1998-10-28 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
EP1238986B1 (en) 1992-10-28 2008-06-25 Genentech, Inc. Use of Vascular endothelial cell growth factor antagonists
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
SG64372A1 (en) 1993-12-17 1999-04-27 Novartis Ag Rapamycin derivatives
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
EP0778263B1 (en) 1994-08-22 2002-01-09 Welfide Corporation Benzene compound and medicinal use thereof
DE69536015D1 (de) 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
AU712193B2 (en) 1995-06-09 1999-10-28 Novartis Ag Rapamycin derivatives
DK0836605T3 (da) 1995-07-06 2002-05-13 Novartis Ag Pyrrolopyrimidiner og fremgangsmåder til deres fremstilling
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
SK284073B6 (sk) 1996-04-12 2004-09-08 Warner-Lambert Company Polycyklické zlúčeniny, ich použitie a farmaceutické kompozície na ich báze
WO1997049688A1 (en) 1996-06-24 1997-12-31 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
US6258823B1 (en) 1996-07-12 2001-07-10 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
CA2265630A1 (en) 1996-09-13 1998-03-19 Gerald Mcmahon Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
RU2198162C2 (ru) * 1997-04-04 2003-02-10 Мицубиси Фарма Корпорейшн Производное 2-аминопропан-1,3-диола, его фармацевтическое применение и промежуточные продукты для их синтеза
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
TW557297B (en) 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
EP1070080A4 (en) * 1998-03-09 2004-12-29 Smithkline Beecham Corp HUMAN EDG-1c POLYNUCLEOTIDES AND POLYPEPTIDES AND THEIR APPLICATIONS
EP1107964B8 (en) 1998-08-11 2010-04-07 Novartis AG Isoquinoline derivatives with angiogenesis inhibiting activity
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
EP2016953A3 (en) 1998-12-22 2009-04-15 Genentech, Inc. Vascular endothelial cell growth factor antagonists and uses thereof
EP1165085B1 (en) 1999-03-30 2006-06-14 Novartis AG Phthalazine derivatives for treating inflammatory diseases
WO2001003739A1 (fr) * 1999-07-12 2001-01-18 Ono Pharmaceutical Co., Ltd. Inhibiteurs de fibrose contenant comme ingredient actif l'agoniste du recepteur de sphingosine-1-phosphate ou la sphingosine-1-phosphate
IL147803A0 (en) 1999-08-24 2002-08-14 Ariad Gene Therapeutics Inc 28-epirapalogs
WO2001058899A1 (en) * 2000-02-09 2001-08-16 Novartis Ag Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase
BR0112484A (pt) 2000-07-13 2003-09-23 Sankyo Co Composto ou um seu sal, éster ou outro derivado farmacologicamente aceitável, composição farmacêutica, uso de um composto ou de um seu sal, éster ou outro derivado farmacologicamente aceitável, e, processo para a preparação do mesmo
AU8533101A (en) 2000-08-31 2002-03-13 Merck & Co Inc Phosphate derivatives as immunoregulatory agents
WO2002045717A1 (en) * 2000-12-06 2002-06-13 Tularik Inc. Lometrexol combination therapy
WO2002076995A2 (en) 2001-03-26 2002-10-03 Novartis Ag 2-amino-propanol derivatives
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
AU2002332289B2 (en) * 2001-09-27 2007-05-10 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivative, addition salt thereof, and immunosuppressant
WO2003029184A1 (en) 2001-09-27 2003-04-10 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivative, addition salt thereof, and immunosuppressant

Also Published As

Publication number Publication date
ATE412408T1 (de) 2008-11-15
PL372103A1 (en) 2005-07-11
HK1126127A1 (en) 2009-08-28
JP2005529921A (ja) 2005-10-06
EP1944026A3 (en) 2011-06-01
NO20130106L (no) 2004-12-03
EP1955696B1 (en) 2014-05-28
CA2483594A1 (en) 2003-11-27
EP1944026B1 (en) 2013-06-26
IL164838A (en) 2013-12-31
HK1073606A1 (en) 2005-10-14
NZ536513A (en) 2007-10-26
AU2003240655B2 (en) 2007-09-06
CN1652757B (zh) 2012-02-08
MXPA04011384A (es) 2005-02-14
EP1955696A3 (en) 2011-05-25
ZA200408575B (en) 2005-07-27
US20090209495A1 (en) 2009-08-20
PT1505959E (pt) 2009-02-05
JP5227492B2 (ja) 2013-07-03
EP1505959A1 (en) 2005-02-16
CA2483594C (en) 2011-02-15
SI1505959T1 (sl) 2009-04-30
WO2003097028A1 (en) 2003-11-27
JP2010100637A (ja) 2010-05-06
NO334074B1 (no) 2013-12-02
EP1505959B1 (en) 2008-10-29
KR20120125398A (ko) 2012-11-14
CN1652757A (zh) 2005-08-10
EP1944026A2 (en) 2008-07-16
EP1955696A2 (en) 2008-08-13
JP2013136584A (ja) 2013-07-11
ES2316758T3 (es) 2009-04-16
CY1108719T1 (el) 2014-04-09
NZ560662A (en) 2009-09-25
BR0311173A (pt) 2005-03-15
IL164838A0 (en) 2005-12-18
IL229559A0 (en) 2014-01-30
IL229550A0 (en) 2014-01-30
US20140303257A1 (en) 2014-10-09
DK1505959T3 (da) 2009-02-23
AU2003240655A1 (en) 2003-12-02
NO20045312L (no) 2004-12-03

Similar Documents

Publication Publication Date Title
DE60324416D1 (de) Verwendung von edg rezeptor bindenden wirkstoffen für die krebstherapie
TWI372628B (en) Methods of modulating cytokine activity; related reagents
BR0116792A (pt) Derivados de diamina de triazol substituìdos como inibidores de quinase
EP1487436A4 (en) POLYTHERAPY FOR TREATING, PREVENTING OR MANAGING PROLIFERATIVE DISORDERS AND CANCERS
CY1112458T1 (el) Ενα αντισωμα ειδικο για διαλυτο baff για χρηση στην αντιμετωπιση του καρκινου
BR0316229A (pt) Métodos de tratamento de câncer e métodos relacionados
BR9814361A (pt) Inibição de quinase raf usando uréiasheterocìclicas substituìdas por arila eheteroarila
MY141605A (en) Method of treating certain cancers using an estrogen agonist/antagonist
ATE438719T1 (de) Spezifischer marker für prostatakrebs
BRPI0411276A (pt) métodos de esgotamento de células b, método de tratamento de neoplasma de células b ou malignidade, método de alìvio de disfunção autoimunológica regulada por células b, composição e artigo industrializado
WO2002092854A3 (en) Genes expressed in breast cancer as prognostic and therapeutic targets
DE60003583D1 (de) Arylaminderivate und ihre verwendung als antitelomerasemittel
MXPA03003632A (es) Metodo para tratamiento de tumores usando terapia de combinacion.
WO2003093794A3 (en) Methods for discovering tumor biomarkers and diagnosing tumors
ITMI991605A0 (it) Follatore per il trattamento di cuoio pelli e simili
AU5302599A (en) Method for diagnosing bone metastasis of malignant tumor
WO2004031775A3 (en) Method for treating or preventing metastasis of colorectal cancers
DK1140147T3 (da) hCG-terapi til behandling af metastatisk brystcancer
BR0212446A (pt) Uso de 4-piridilmetilftalazinas para tratamento de câncer
CY1114433T1 (el) Χρηση παραγοντων που προσδενονται στον υποδοχεα edg στον καρκινο
WO2002056753A3 (en) P27 prevents cellular migration
AU2228299A (en) Composition and method for treating metastatic tumors or cancer induced by cellsexpressing sv40 tumor antigen
AU2002231874A1 (en) Use of semaphorin 3a for diagnosing and treating cancer, especially prostate cancer
UA49216A (uk) Засіб для лікування ускладнень після видалення злоякісних новоутворень шкіри
WO2004111262A8 (en) Method of identifying a selective chemotherapeutic agent

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN